Dr. Yuk-Ching Tse-Dinh, Professor & Director of the Biomolecular Sciences Institute, has been appointed to serve at the National Institutes of Health (NIH) Partnerships for Countermeasures Against Select Pathogens, Therapeutics, Immunotherapeutics, and Vaccines Review Panel on February 28, 2017.
The National Institute of Allergy and Infectious Diseases initiated the partnerships program for translational research to support research, development, and eventual commercialization of candidate products to address potential biological pathogen threats. The program has also been used to address high priority emerging diseases, such as SARS and avian influenza.
The Partnerships program has uniquely fostered many new research collaborations between experts from different disciplines of academia and industry to address a substantial and immediate public health threat. This concerted effort has significantly accelerated preclinical development of numerous new or improved countermeasures against many Category A, B, or C agents. Continued support of this program will provide for advanced development of newly validated candidate products.
Under this program, NIAID has supported more than 500 awards for the development of therapeutics, vaccines, and diagnostics. A number of candidate products developed through this program have advanced sufficiently to have gained U.S. Department of Health and Human Services contract support for further development, including multiple anthrax countermeasures (vaccines, anti-toxin monoclonal antibodies and polyclonal antibodies); a novel influenza therapeutic; an immunostimulatory patch; a cell culture-derived Influenza vaccine; a topical microbicide; and several diagnostic devices.
For more information, click here